Vaccine and Infectious Disease Division
M. Juliana McElrath has not added Biography.
If you are M. Juliana McElrath and would like to personalize this page please email our Author Liaison for assistance.
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response.
PLoS pathogens Apr, 2009 | Pubmed ID: 19343217
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.
Journal of acquired immune deficiency syndromes (1999) Mar, 2002 | Pubmed ID: 11873074
Progress in the development of a preventive HIV-1 vaccine.
Clinics in laboratory medicine Dec, 2002 | Pubmed ID: 12489290
Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection.
Journal of virology Feb, 2003 | Pubmed ID: 12552005
Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity.
The Journal of infectious diseases Jan, 2003 | Pubmed ID: 12552447
Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals.
Journal of virology Jun, 2003 | Pubmed ID: 12743268
Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection.
Journal of virology Jun, 2003 | Pubmed ID: 12768006
HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals.
Journal of immunology (Baltimore, Md. : 1950) Jul, 2003 | Pubmed ID: 12847284
Most highly exposed seronegative men lack HIV-1-specific, IFN-gamma-secreting T cells.
Journal of immunology (Baltimore, Md. : 1950) Sep, 2003 | Pubmed ID: 12928421
Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy.
Clinical immunology (Orlando, Fla.) Sep, 2003 | Pubmed ID: 14499244
Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection.
Journal of immunology (Baltimore, Md. : 1950) Oct, 2003 | Pubmed ID: 14500685
Broadly increased sensitivity to cytotoxic T lymphocytes resulting from Nef epitope escape mutations.
Journal of immunology (Baltimore, Md. : 1950) Oct, 2003 | Pubmed ID: 14530319
Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion.
The Journal of infectious diseases Dec, 2003 | Pubmed ID: 14673757
Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease.
The Journal of infectious diseases Feb, 2004 | Pubmed ID: 14745710
Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
The Journal of infectious diseases Apr, 2004 | Pubmed ID: 15031791
Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials.
Journal of immunological methods May, 2004 | Pubmed ID: 15183082
Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele.
Journal of immunology (Baltimore, Md. : 1950) Aug, 2004 | Pubmed ID: 15265949
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
The Journal of infectious diseases Sep, 2004 | Pubmed ID: 15295694
Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1.
The Journal of infectious diseases Sep, 2004 | Pubmed ID: 15319853
Effect of adjunct hydroxyurea on helper T cell immunity in HIV type 1-infected patients with virological suppression.
AIDS research and human retroviruses Aug, 2004 | Pubmed ID: 15320983
Correlation between interferon- gamma secretion and cytotoxicity, in virus-specific memory T cells.
The Journal of infectious diseases Nov, 2004 | Pubmed ID: 15478077
Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.
The Journal of infectious diseases Dec, 2004 | Pubmed ID: 15529261
Most DC-SIGNR transcripts at mucosal HIV transmission sites are alternatively spliced isoforms.
European journal of human genetics : EJHG Jun, 2005 | Pubmed ID: 15812562
High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.
The Journal of infectious diseases Oct, 2005 | Pubmed ID: 16136469
Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission.
Journal of virology Sep, 2005 | Pubmed ID: 16140745
CD4+ T cell receptor repertoire perturbations in HIV-1 infection: association with plasma viremia and disease progression.
Clinical immunology (Orlando, Fla.) Apr, 2006 | Pubmed ID: 16403675
Repeat-region polymorphisms in the gene for the dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related molecule: effects on HIV-1 susceptibility.
The Journal of infectious diseases Mar, 2006 | Pubmed ID: 16453266
Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection.
Journal of virology Mar, 2006 | Pubmed ID: 16474153
Abacavir hypersensitivity reaction in primary HIV infection.
AIDS (London, England) Jun, 2006 | Pubmed ID: 16816555
Selection on the human immunodeficiency virus type 1 proteome following primary infection.
Journal of virology Oct, 2006 | Pubmed ID: 16973556
Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.
Journal of virology Oct, 2006 | Pubmed ID: 16973582
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Vaccine Jan, 2007 | Pubmed ID: 17049679
Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection.
Journal of immunology (Baltimore, Md. : 1950) Nov, 2006 | Pubmed ID: 17082660
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.
Journal of acquired immune deficiency syndromes (1999) Feb, 2007 | Pubmed ID: 17106277
Comprehensive epitope analysis of cross-clade Gag-specific T-cell responses in individuals with early HIV-1 infection in the US epidemic.
Vaccine Jan, 2007 | Pubmed ID: 17112643
Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1.
Immunity Feb, 2007 | Pubmed ID: 17306567
Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection.
Journal of virology May, 2007 | Pubmed ID: 17329342
Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.
Journal of immunological methods Apr, 2007 | Pubmed ID: 17382342
Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.
Journal of virology Jun, 2007 | Pubmed ID: 17392364
Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination.
Journal of immunological methods May, 2007 | Pubmed ID: 17451739
Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.
Journal of virology Sep, 2007 | Pubmed ID: 17582003
Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape.
Journal of virology Nov, 2007 | Pubmed ID: 17728222
A framework for assessing immunological correlates of protection in vaccine trials.
The Journal of infectious diseases Nov, 2007 | Pubmed ID: 17922394
Novel cytotoxic T-lymphocyte escape mutation by a three-amino-acid insertion in the human immunodeficiency virus type 1 p6Pol and p6Gag late domain associated with drug resistance.
Journal of virology Jan, 2008 | Pubmed ID: 17942528
Setting the stage: host invasion by HIV.
Nature reviews. Immunology Jun, 2008 | Pubmed ID: 18469831
Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials.
Cytometry. Part A : the journal of the International Society for Analytical Cytology Sep, 2008 | Pubmed ID: 18615598
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.
Vaccine Jan, 2009 | Pubmed ID: 18996425
Impaired viral entry cannot explain reduced CD4+ T cell susceptibility to HIV type 1 in certain highly exposed individuals.
AIDS research and human retroviruses Nov, 2008 | Pubmed ID: 19000021
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Lancet Nov, 2008 | Pubmed ID: 19012954
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.
Lancet Nov, 2008 | Pubmed ID: 19012957
Post-step modifications for research on HIV vaccines.
AIDS (London, England) Jan, 2009 | Pubmed ID: 19050380
T cell responses generated by HIV vaccines in clinical trials.
Current opinion in HIV and AIDS May, 2008 | Pubmed ID: 19372993
Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells.
Journal of virology Oct, 2009 | Pubmed ID: 19706707
Preinfection human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes failed to prevent HIV type 1 infection from strains genetically unrelated to viruses in long-term exposed partners.
Journal of virology Oct, 2009 | Pubmed ID: 19706711
Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.
Journal of virology Jan, 2010 | Pubmed ID: 19846512
Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals.
AIDS (London, England) Nov, 2009 | Pubmed ID: 19855253
Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses.
The Journal of infectious diseases Dec, 2009 | Pubmed ID: 19909083
Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells.
Antimicrobial agents and chemotherapy Feb, 2010 | Pubmed ID: 19949052
Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype.
Journal of virology May, 2010 | Pubmed ID: 20147397
In situ detection of Gag-specific CD8+ cells in the GI tract of SIV infected Rhesus macaques.
Retrovirology , 2010 | Pubmed ID: 20158906
HIV vaccines: mosaic approach to virus diversity.
Nature medicine Mar, 2010 | Pubmed ID: 20208511
Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms.
The Journal of biological chemistry Sep, 2010 | Pubmed ID: 20615867
Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.
PloS one , 2010 | Pubmed ID: 20706632
Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection.
The Journal of infectious diseases Oct, 2010 | Pubmed ID: 20846040
Induction of immunity to human immunodeficiency virus type-1 by vaccination.
Immunity Oct, 2010 | Pubmed ID: 21029964
Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).
PloS one , 2010 | Pubmed ID: 21048953
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
Science (New York, N.Y.) Dec, 2010 | Pubmed ID: 21051598
Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.
PloS one , 2010 | Pubmed ID: 21085486
Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study.
AIDS (London, England) Jan, 2011 | Pubmed ID: 21150554
Equivalence of ELISpot assays demonstrated between major HIV network laboratories.
PloS one , 2010 | Pubmed ID: 21179404
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.
Vaccine Feb, 2011 | Pubmed ID: 21216311
Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.
The Journal of infectious diseases Mar, 2011 | Pubmed ID: 21278214
Dynamics of viral evolution and CTL responses in HIV-1 infection.
PloS one , 2011 | Pubmed ID: 21283794
Standing guard at the mucosa.
Immunity Feb, 2011 | Pubmed ID: 21349427
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.
Nature medicine Mar, 2011 | Pubmed ID: 21358627
Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles.
PLoS pathogens Feb, 2011 | Pubmed ID: 21383976
Association between peripheral γδ T-cell profile and disease progression in individuals infected with HIV-1 or HIV-2 in West Africa.
Journal of acquired immune deficiency syndromes (1999) Jun, 2011 | Pubmed ID: 21423026
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.
The Journal of infectious diseases Apr, 2011 | Pubmed ID: 21451004
Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28.
Blood Jun, 2011 | Pubmed ID: 21493800
Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.
PloS one , 2011 | Pubmed ID: 21533229
Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes.
Journal of virology Aug, 2011 | Pubmed ID: 21593162
Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.
PloS one , 2011 | Pubmed ID: 21695251
Vaccine-induced HIV-specific CD8+ T cells utilize preferential HLA alleles and target-specific regions of HIV-1.
Journal of acquired immune deficiency syndromes (1999) Nov, 2011 | Pubmed ID: 21709567
Host genetic polymorphisms associated with innate immune factors and HIV-1.
Current opinion in HIV and AIDS Sep, 2011 | Pubmed ID: 21734565
Protective HIV-specific CD8+ T cells evade Treg cell suppression.
Nature medicine Aug, 2011 | Pubmed ID: 21765403
HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable.
Journal of immunology (Baltimore, Md. : 1950) Sep, 2011 | Pubmed ID: 21844392
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
PloS one , 2011 | Pubmed ID: 21857901
Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.
PloS one , 2011 | Pubmed ID: 21931737
Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects.
The Journal of infectious diseases Nov, 2011 | Pubmed ID: 21940420
Vaginal langerhans cells nonproductively transporting HIV-1 mediate infection of T cells.
Journal of virology Dec, 2011 | Pubmed ID: 21976645
Profiling immunity to HIV vaccines with systems biology.
Current opinion in HIV and AIDS Jan, 2012 | Pubmed ID: 22134340
Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure.
PloS one , 2011 | Pubmed ID: 22174851
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.
The Journal of clinical investigation Jan, 2012 | Pubmed ID: 22201684
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
The New England journal of medicine Apr, 2012 | Pubmed ID: 22475592
Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
PloS one , 2012 | Pubmed ID: 22496775
Vpu Mediates Depletion of Interferon Regulatory Factor 3 during HIV Infection by a Lysosome-Dependent Mechanism.
Journal of virology Aug, 2012 | Pubmed ID: 22593165
Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells.
Journal of immunological methods Aug, 2012 | Pubmed ID: 22626638
Vpu-Deficient HIV Strains Stimulate Innate Immune Signaling Responses in Target Cells.
Journal of virology Aug, 2012 | Pubmed ID: 22647704
Two new monoclonal antibodies for biochemical and flow cytometric analyses of human interferon regulatory factor-3 activation, turnover, and depletion.
Methods (San Diego, Calif.) Jun, 2012 | Pubmed ID: 22705311
Is an HIV vaccine possible?
Journal of acquired immune deficiency syndromes (1999) Aug, 2012 | Pubmed ID: 22772390
A Novel HIV Vaccine Adjuvanted by IC31 Induces Robust and Persistent Humoral and Cellular Immunity.
PloS one , 2012 | Pubmed ID: 22848738
Quantifying Ongoing HIV-1 Exposure in HIV-1-Serodiscordant Couples to Identify Individuals With Potential Host Resistance to HIV-1.
The Journal of infectious diseases Aug, 2012 | Pubmed ID: 22926009
MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load.
PloS one , 2012 | Pubmed ID: 22952672
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유